Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies

Area of Science:

• Neurology
• Genetics
• Structural Biology

Background:

• Epilepsy is a common chronic neurological disorder affecting 1-2% of the global population.
• A significant portion (30%) of epilepsy cases exhibit drug resistance, posing a major clinical challenge.
• Genomic mutations are implicated in epilepsy etiology, with potential for improved treatment strategies.

Purpose of the Study:

• To review the role of genetic polymorphisms and mutations in epilepsy, particularly drug-resistant epilepsy.
• To explore the integration of transcriptomics, structural biology, and pharmacogenomics for personalized epilepsy medicine.
• To highlight the therapeutic potential of understanding mutation effects on protein structures for drug development.

Main Methods:

• Review of existing genetic association studies for epilepsy and drug resistance.
• Analysis of the impact of mutations on protein structure and biophysics.
• Integration of multi-omics data (transcriptomics, genomics) and clinical data.

Main Results:

• Few studies have investigated the direct impact of mutations on protein structure and biophysics in epilepsy.
• Genomic insights offer potential for predicting drug response and developing novel antiepileptic drugs.
• Individualized medicine approaches integrating genetic data show promise for improving treatment outcomes.

Conclusions:

• Understanding the structural and biophysical effects of genomic mutations is crucial for advancing epilepsy treatment.
• Personalized medicine strategies incorporating genetic, transcriptomic, and pharmacokinetic data can enhance antiepileptic drug efficacy.
• Further research integrating structural biology and pharmacogenomics is needed to realize the full therapeutic potential for drug-resistant epilepsy.